Dr. Reddy's receives 7 observations from USFDA after inspection at Srikakulam plant
Dr. Reddy's Laboratories Ltd. announced on July 18 that the United States Food & Drug Administration (USFDA) has completed a Good Manufacturing Practice (GMP) and Pre-Approval Inspection (PAI) at its formulations manufacturing facility FTO 11, located in Srikakulam, Andhra Pradesh.
According to the company's filing with stock exchanges, the inspection was conducted over eight days, from July 10 to July 18, 2025. At the conclusion of the inspection, the USFDA issued a Form 483 with seven observations.
Dr. Reddy's stated that it would address the observations within the stipulated timeline, as per regulatory requirements.
The company said the disclosure was made under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and is meant for public record and investor information.
The Hyderabad-headquartered pharmaceutical major operates several manufacturing facilities in India and abroad, and this development comes as part of its routine regulatory inspections for ongoing compliance and product approvals.
Disclaimer: This information is based solely on the company's official disclosure dated July 18, 2025. Business Upturn or the author is not liable for any actions taken based on this information. Investors are advised to independently verify and consult financial advisors before making investment decisions.
Ahmedabad Plane Crash
Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
15 minutes ago
- Business Upturn
Bharti Airtel completes 5% stake acquisition in Ericsson's Aduna Global Holding LLC
By Aditya Bhagchandani Published on July 29, 2025, 13:07 IST Bharti Airtel Ltd has announced the successful completion of its acquisition of approximately 5% membership interest in Aduna Global Holding LLC, a venture established by Ericsson in collaboration with global communication service providers. This follows the company's earlier intimation dated October 31, 2024, regarding its entry into a Membership Interest Purchase Agreement for the stake. Aduna is focused on aggregating and globally selling network Application Programming Interfaces (APIs)—a key area for future telecom innovation. The completion of this strategic investment marks Bharti Airtel's growing push into next-gen telecom technologies and open network platforms. The deal aims to enhance interoperability and monetization opportunities through standardized API exposure across global networks. Ericsson also issued a press release confirming the completion of the Aduna transaction. Disclaimer: This article is for informational purposes only and should not be considered financial or investment advice. Investors are advised to consult certified professionals before making investment decisions. Ahmedabad Plane Crash Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.
Business Upturn
32 minutes ago
- Business Upturn
AstraZeneca Pharma shares in focus as global parent reports Q2 results
AstraZeneca Pharma shares were in focus on Tuesday after its global parent reported better-than-expected results for the second quarter of 2025, driven by strong performance in its oncology portfolio. For Q2, AstraZeneca reported revenue of $14.46 billion, ahead of the $14.12 billion estimate. Core earnings per share stood at $2.17, in line with projections, and the core operating margin remained steady at 32%. One of the key highlights was Imfinzi, a major cancer drug, which clocked $1.46 billion in revenue, surpassing expectations of $1.34 billion. The company declared an interim dividend of $1.03 per share and reiterated its full-year 2025 guidance, expecting high single-digit percentage growth in total revenue and low double-digit growth in core EPS. AstraZeneca Pharma shares traded in a narrow range on July 29, moving between ₹8,865.50 and ₹9,000.00 during the session. The stock opened at ₹8,944.50, slightly above its previous close of ₹8,937.50. Despite the subdued movement, the stock remains significantly above its 52-week low of ₹6,220.00, though still below the 52-week high of ₹10,691.00. Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information. Ahmedabad Plane Crash Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
Business Upturn
4 hours ago
- Business Upturn
Flair Writing shares jump 6% as Q1 revenue rises 16.6% YoY to Rs 288 crore, Ebitda up 17.7%
By Aman Shukla Published on July 29, 2025, 09:43 IST Flair Writing Industries Ltd shares surged over 6% in Tuesday's trade after the company reported robust financial results for the first quarter of FY26. Flair Writing Q1FY26 Results For the quarter ended June 30, 2025, Flair Writing reported a 16.6% increase in consolidated revenue to Rs 288 crore, compared to Rs 247 crore in Q1FY25. The company's operating performance also improved, with EBITDA rising 17.7% to Rs 48.94 crore, against Rs 41.57 crore a year ago. EBITDA margin expanded by 16 basis points to 16.99%. Net profit for the quarter stood at Rs 28.6 crore, up 7.9% YoY from Rs 26.5 crore in the same period last year. Stock Performance Flair Writing shares opened at Rs 315.00 and touched an intraday high of Rs 338.10, close to its 52-week high of Rs 342.50. The stock hit a low of Rs 313.10 during the session. As of the latest update, it was trading 6% higher over its previous close of Rs 317.80. Notably, the stock has surged significantly from its 52-week low of Rs 194.03. Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information. Ahmedabad Plane Crash Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
